Objective . Genetic tests for hereditary hemochromatosis (HH) are currently included in the German ambulatory care reimbursement scheme but only for symptomatic individuals and the offspring of HH patients. This study synthesizes the most current evidence to examine whether screening in the broader population is cost-effective and to identify the best choice of initial and follow-up screening tests.Methods. A probabilistic decision-analytic model was constructed to calculate cost per life year gained (LYG) for HH screening among male Caucasians aged 30. Three strategies were considered in both the general population and male offspring of HH patients: phenotypic (transferrin saturation, TS), genotypic (C282Y mutation), and sequential (genotype if TS is elevated) screening.Results. The incremental cost-effectiveness of sequential screening among male offspring, sequential population-wide screening, and genotypic screening is 41 000, 124 000, and 161 000 /LYG, respectively. All other strategies were subject to simple or extended dominance. The results are subject to high uncertainty. The most influential parameters in the deterministic one-way sensitivity analysis are discounting of life years gained and the adherence of patients to preventive phlebotomy.Discussion . The current German policy of only screening at-risk individuals is consistent with health economic decision making based on typically accepted thresholds. However, conducting the DNA test after the first elevated TS result is more cost-effective than waiting for a second TS result as recommended by the German guidelines. Further empirical work regarding adherence to long-term prevention recommendations and explicit and well-justified guidance for the choice of discount rates in German economic evaluation are needed.
Human Genome Program.Genomics and Its Impact on Science and Society: A 2003 Primer. 2003 [cited 30 August 2005]. Available from: www.ornl.gov/hgmis/publicat/primer/
2.
Guttmacher AE , Collins FSGenomic medicine: a primer. N Engl J Med. 2002;347:1512-20.
3.
Rogowski W.Current impact of gene technology on healthcare: a map of economic assessments . Health Pol. 2007;80:340-57.
4.
Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PRScreening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006;145: 209-23.
Adams PC, Gregor JC, Kertesz AE, Valberg LSScreening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology. 1995;109:177-88.
7.
Adams PC, Kertesz AE, Valberg LSScreening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness . Hepatology. 1995;22:1720-7.
8.
Adams PC, Valberg LSScreening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol . 1999;94:1593-600.
9.
Asberg A., Tretli S., Hveem K., Bjerve KSBenefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37:1212-9.
10.
Buffone GJ, Beck JRCost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem. 1994;40:1631-6.
11.
El-Serag HB , Inadomi JM, Kowdley KVScreening for hereditary hemochromatosis in siblings and children of affected patients: a cost-effectiveness analysis . Ann Intern Med. 2000;132: 261-9.
12.
Gagné G., Reinharz D., Laflamme N., Adams P., Rousseau F.Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007;71:46-58.
13.
Schöffski O. , Schmidtke J., Stuhrmann M.Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genetics. 2000;3:2-11.
14.
Stave GM, Mignogna JJ, Powell GS, Hunt CMEvaluation of a workplace hemochromatosis screening program. Am J Prev Med. 1999;16:303-6.
15.
Rogowski W.Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22:327-37.
16.
Ioannidis JP , Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DGReplication validity of genetic association studies. Nat Genet . 2001;29:306-9.
17.
Schmitt B., Golub RM, Green R.Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med. 2005;143:522-36.
18.
Adams PC, Passmore L., Chakrabarti S., et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol. 2006;4:918-23; quiz 807.
19.
Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload- related disease in HFE hereditary hemochromatosis . N Engl J Med. 2008;358:221-30.
20.
Philips Z., Bojke L., Sculpher M., Claxton K., Golder S.Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355-71.
21.
Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-78.
22.
Krawczak M. , Cooper DN, Schmidtke J.Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet . 2001;69:361-70.
23.
Stuhrmann M. , Hoy L., Nippert I., Schmidtke J.Genotype-based screening for hereditary hemochromatosis: II. Attitudes toward genetic testing and psychosocial impact-a report from a German pilot study. Genet Test. 2005;9:242-54.
24.
Gabriel H., Stuhrmann M.Leitlinie zur molekulargenetischen Diagnostik der hereditären Hämochromatose . Medizinische Genetik. 2006;18:273-8.
25.
Stuhrmann M. , Strassburg C., Schmidtke J.Genotype-based screening for hereditary haemochromatosis: I. Technical performance, costs and clinical relevance of a German pilot study . Eur J Hum Genet. 2005;13:69-78.
26.
Phatak PD, Guzman G., Woll JE, Robeson A., Phelps CECost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994;154:769-76.
27.
Briggs A., Claxton K., Sculpher M.Decision Modelling for Health Economic Evaluation. Oxford , UK: Oxford University Press;2006 .
28.
Olynyk JK, Hagan SE, Cullen DJ, Beilby J., Whittall DEEvolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004;79:309-13.
29.
Andersen RV , Tybjaerg-Hansen A., Appleyard M., Birgens H., Nordestgaard BGHemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004 ;103:2914-9.
30.
Olynyk JK, Cullen DJ, Aquilia S., Rossi E., Summerville L., Powell LWA population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-24.
31.
Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830-6.
32.
Delatycki MB , Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet . 2005;366:314-6.
33.
Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294-301.
34.
Adams PC, Reboussin DM, Press RD, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007;120:999.e1-7.
35.
Hicken BL, Tucker DC, Barton JCPatient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol. 2003;98:2072-7.
36.
Siegel JE, Weinstein MC, Russell LB, Gold MRRecommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41.
37.
Krauth C., Hessel F., Klingelhofer HE, Schweikert B., Hansmeier T., Wasem J.Empirische Bewertungssätze in der gesundheitsöko nomischen Evaluation: Ein Vorschlag der AG Gesundheitsökonomische Methoden (AG MEG). Rehabilitation (Stuttg). 2005;44: 297-306.
38.
von der Schulenburg JMG , Greiner W., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus . Gesundh Okon Qual Manage. 2007;12:285-90.
39.
Winkelmayer WC , Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JSHealth economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417-30.
40.
National Institute for Health and Clinical Excellence.Guide to the methods of technology appraisal. 2004 [cited 17 May 2005]. Available from: http://www.nice.org.uk/pdf/TAP_Methods.pdf
McDonald HP, Garg AX, Haynes RBInterventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-79.
43.
Haynes RB, McDonald H., Garg AX, Montague P.Interventions for helping patients to follow prescriptions for medications . Cochrane Database Syst Rev. 2002;(2):CD000011.
44.
Niederau C. , Fischer R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G.Long-term survival in patients with hereditary hemochromatosis. Gastroenterology . 1996;110:1107-9.
45.
Milman N., Pedersen P., á Steig T., Byg KE, Graudal N., Fenger K.Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol. 2001;80:737-44.
46.
Grosse SD, Khoury MJWhat is the clinical utility of genetic testing? Genet Med . 2006;8:448-50.
47.
Khoury MJ, McCabe LL, McCabe ERPopulation screening in the age of genomic medicine. N Engl J Med. 2003;348:50-8.
48.
Power TE, Adams PC, Barton JC, et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test. 2007;11:55-64.
49.
Institute for Quality and Efficiency in Health Care.Methods for assessment of the relation of benefits to costs in the German statutory health care system. 2008 [cited 24 Jan 2008]. Available from: http://www.iqwig.de/download/08-01-24_Methods_of_the_Relation_of_Benefits_to_Costs_Version_1_0.pdf
50.
Adams PC, Speechley M., Kertesz AELong-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991; 101:368-72.
51.
Palomaki GE , Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WWEstimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing . Genet Med. 2003;5:440-3.
52.
Bomford A., Williams R.Long term results of venesection therapy in idiopathic haemochromatosis . Q J Med. 1976;45:611-23.
53.
Nisselle AE , Delatycki MB, Collins V., et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis . Clin Genet . 2004;65:358-67.
54.
Barton JC, Acton RT, Dawkins FW, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005;9:231-41.
55.
Barton JC, Acton RT, Leiendecker-Foster C., et al. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007;11:269-75.
56.
Adams PC, Reboussin DM, Leiendecker-Foster C., et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Clin Chem. 2005; 51:1048-52.
57.
Altenstetter C., Busse R.Health care reform in Germany: patchwork change within established governance structures. J Health Polit Policy Law. 2005;30:121-42.
58.
McCune CA, Ravine D., Worwood M., Jackson HA, Evans HM, Hutton D.Screening for hereditary haemochromatosis within families and beyond. Lancet . 2003;362:1897-8.
